Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody

You likely can't join if

• History of inflammatory bowel disease (eg, ulcerative colitis, Crohn’s disease, microscopic colitis). Participant with a non - CDI (C. difficile infection) condition such that the participant routinely passes loose stool (eg, patients with an ostomy) Planned surgery for C. difficile infection within 24 hours of enrollment Current toxic megacolon and/or small bowel ileus Any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, ie, restrictive procedures such as banding, are permitted). Major gastrointestinal surgery as assessed by the Investigator (eg, significant bowel resection or diversion) within 90 days before enrollment (this does not include appendectomy or cholecystectomy) Due to receive more than 25 days of antibacterial drug therapy for C. difficile infection for the qualifying C. difficile infection episode Treatment with a fecal donor transplant or fecal microbiota product in the 180 days before IMP administration, are receiving or planned administration for the qualifying episode of C. difficile infection, or planned administration during the 180 days after IMP administration Treatment with bezlotoxumab in the 180 days before IMP administration, are receiving or planned administration for the qualifying episode of CDI, or planned administration during the 180 days after IMP administration Oral cholestyramine, oral nitazoxanide, oral rifaximin; IV tigecycline, or oral or IV fusidic acid treatment in the 2 days before IMP administration, or due to receive more than a 24 - hour regimen of any of these medications in the 180 days after IMP administration (ie, cannot stop or avoid them) Administration of any licensed vaccine within 14 days before, or planned administration within 14 days, after IMP administration Receipt of human immunoglobulin to a total dose of > 0.7 g/kg (via any route) within the 4 - week period before IMP administration, or planned administration of a total dose > 0.7 mg/kg over any 4 - week period from IMP administration during the 180 days after IMP administration Medications given to decrease gastrointestinal peristalsis, such as loperamide (Imodium™) or diphenoxylate hydrochloride/atropine sulfate (Lomotil™) planned at any time during the 14 days after IMP administration. Participants receiving opioid medications at the onset of diarrhea. (They may be included if they are expected to be on stable doses of these medications or there is anticipation of a dose decrease or cessation of their use.)